864947-20-6

Basic information

• Product Name: 3-Azabicyclo[3.1.0]hexane-2-carboxaMide, N-[1-(cyclopropylMethyl)-2,3-dioxo-3-(2-propen-1-ylaMino)propyl]-3-[(2S)-2-[[[[(1S)-1-[(4,4-diMethyl-2,6-dioxo-1-piperidinyl)Methyl]-2,2-diMethylpropyl]aMino]carbonyl]aMino]-3,3-diMethyl-1-oxobutyl]-6,6-diMethyl-
• Synonyms: 3-Azabicyclo[3.1.0]hexane-2-carboxaMide, N-[1-(cyclopropylMethyl)-2,3-dioxo-3-(2-propen-1-ylaMino)propyl]-3-[(2S)-2-[[[[(1S)-1-[(4,4-diMethyl-2,6-dioxo-1-piperidinyl)Methyl]-2,2-diMethylpropyl]aMino]carbonyl]aMino]-3,3-diMethyl-1-oxobutyl]-6,6-diMethyl-;N-[1-cyclopropyl-3,4-dioxo-4-(prop-2-enylamino)butan-2-yl]-3-[(2S)-2-[[(2S)-1-(4,4-dimethyl-2,6-dioxopiperidin-1-yl)-3,3-dimethylbutan-2-yl]carbamoylamino]-3,3-dimethylbutanoyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
• CAS NO: 864947-20-6
• Molecular Formula: C38H60N6O7
• Molecular Weight: 712.919
• Mol File: 864947-20-6.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-Azabicyclo[3.1.0]hexane-2-carboxaMide, N-[1-(cyclopropylMethyl)-2,3-dioxo-3-(2-propen-1-ylaMino)propyl]-3-[(2S)-2-[[[[(1S)-1-[(4,4-diMethyl-2,6-dioxo-1-piperidinyl)Methyl]-2,2-diMethylpropyl]aMino]carbonyl]aMino]-3,3-diMethyl-1-oxobutyl]-6,6-diMethyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3-Azabicyclo[3.1.0]hexane-2-carboxaMide, N-[1-(cyclopropylMethyl)-2,3-dioxo-3-(2-propen-1-ylaMino)propyl]-3-[(2S)-2-[[[[(1S)-1-[(4,4-diMethyl-2,6-dioxo-1-piperidinyl)Methyl]-2,2-diMethylpropyl]aMino]carbonyl]aMino]-3,3-diMethyl-1-oxobutyl]-6,6-diMethyl-(864947-20-6)
• EPA Substance Registry System: 3-Azabicyclo[3.1.0]hexane-2-carboxaMide, N-[1-(cyclopropylMethyl)-2,3-dioxo-3-(2-propen-1-ylaMino)propyl]-3-[(2S)-2-[[[[(1S)-1-[(4,4-diMethyl-2,6-dioxo-1-piperidinyl)Methyl]-2,2-diMethylpropyl]aMino]carbonyl]aMino]-3,3-diMethyl-1-oxobutyl]-6,6-diMethyl-(864947-20-6)

Safety Data

• Hazardous Substances Data: 864947-20-6(Hazardous Substances Data)

Relevant articles and documents

Second-generation highly potent and selective inhibitors of the hepatitis C virus NS3 serine protease

The hepatitis C virus (HCV) infection is a leading cause of chronic liver disease. The moderate efficacy along with side effects of the current pegylated interferon and ribavirin combination therapy underscores the need for more effective and safer new tr

NOVEL KETOAMIDES WITH CYCLIC P4'S AS INHIBITORS OF NS3 SERINE PROTEASE OF HEPATITIS C VIRUS

The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease.